Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silence Therapeutics Plc - American Depository Share
(NQ:
SLN
)
6.880
+0.540 (+8.52%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
984,125
Open
6.280
Bid (Size)
6.120 (2)
Ask (Size)
7.090 (1)
Prev. Close
6.340
Today's Range
6.160 - 7.090
52wk Range
5.810 - 27.72
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Top 3 Health Care Stocks That May Explode In Q4
December 18, 2024
Via
Benzinga
The Analyst Landscape: 6 Takes On Silence Therapeutics
December 10, 2024
Via
Benzinga
Performance
YTD
-62.91%
-62.91%
1 Month
-1.85%
-1.85%
3 Month
-61.78%
-61.78%
6 Month
-66.21%
-66.21%
1 Year
-59.51%
-59.51%
More News
Read More
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
December 09, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Silence Therapeutics plc
Via
Business Wire
Analyst Scoreboard: 4 Ratings For Silence Therapeutics
November 15, 2024
Via
Benzinga
Analyst Expectations For Silence Therapeutics's Future
August 16, 2024
Via
Benzinga
The Analyst Landscape: 6 Takes On Silence Therapeutics
June 20, 2024
Via
Benzinga
What 7 Analyst Ratings Have To Say About Silence Therapeutics
May 17, 2024
Via
Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
November 19, 2024
Via
Benzinga
Top 3 Health Care Stocks You'll Regret Missing In Q4
November 19, 2024
Via
Benzinga
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
November 18, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
August 27, 2024
From
Silence Therapeutics plc
Via
Business Wire
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
August 15, 2024
Via
InvestorPlace
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 15, 2024
From
Silence Therapeutics plc
Via
Business Wire
The 3 Best Gene Editing Stocks to Buy in August 2024
August 07, 2024
Via
InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
July 25, 2024
Via
InvestorPlace
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
June 27, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
June 24, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
June 20, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Silence Therapeutics plc
Via
Business Wire
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
May 16, 2024
Via
InvestorPlace
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
May 16, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
April 30, 2024
From
Silence Therapeutics plc
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.